atomoxetine / Generic mfg. - LARVOL DELTA

Exposures to attention deficient hyperactivity disorder medications reported to the New South Wales Poisons Information Centre (2014-2023): A retrospective study. (PubMed, Aust N Z J Psychiatry) - "Exposures to attention deficit hyperactivity disorder medications present a growing public health issue. Rates have risen annually over the past decade, and the majority require medical attention, placing strain on healthcare resources. There are notable differences in exposure patterns among affected age groups. This highlights the need for targeted preventive measures focused on both quality use of the medication being prescribed as well as considering the circumstances and safety of the individual and household."

Journal • Retrospective data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

An efficient neural network of cooperating serotonergic and noradrenergic neurons in modulating sudden unexpected death in epilepsy. (PubMed, Int J Biol Sci) - "Through a combination of pharmacological interventions, calcium signal recordings, and optogenetics, results show that elevating 5-HT and NE levels via 5-hydroxytryptophan and the norepinephrine reuptake inhibitor atomoxetine significantly reduced SUDEP incidence, with evidence of a robust synergistic interaction. Furthermore, venlafaxine, a selective serotonin-norepinephrine reuptake inhibitor, enhances the cooperative regulation of 5-HT and NE, further supporting their combined protective role...Targeted administration of the 5-HT2A/NE α-1 receptor antagonist and agonist into the PBC reveal their pivotal roles in mediating the protective effects of 5-HT and NE. Our study reveals that serotonergic and noradrenergic systems synergistically regulate SUDEP, and further identifies that the DR-LC-PBC neural circuit exerts a protective effect through activation of 5-HT2A and NE-α1 receptors within the PBC."

Journal • CNS Disorders • Epilepsy

Attention-deficit hyperactivity disorder medication use in pregnancy and risk of miscarriage. (PubMed, Br J Psychiatry) - "ADHD medication use during pregnancy is associated with increased miscarriage risk. However, filled prescriptions may not reflect actual use. Further research is needed to clarify these associations and refine risk estimates."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

A randomised controlled trial to evaluate the clinical and cost-effectiveness of Stimulant compared with Non-stimulant medication for adults with Attention-deficit/hyperactivity disorder and a history of Psychosis or biPolar disordER: SNAPPER. (PubMed, Trials) - "Given that untreated ADHD is associated with poor clinical outcomes, unemployment and criminal justice system involvement, clear evidence in this area is likely to improve recovery for individuals with ADHD and a history of SMI, reducing costs for the individual, the NHS and society."

HEOR • Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Bipolar Disorder • CNS Disorders • Developmental Disorders • Mood Disorders • Psychiatry

Exploring Ferroptosis-Related Genes in Depression: Insights Into Molecular Mechanisms and Potential Therapies. (PubMed, Int J Gen Med) - "We identified five potential small-molecule compounds (VX-702, gossypol, atomoxetine, TWS-119, and ibudilast) that may target these ferroptosis-related pathways...This study provides evidence supporting the involvement of ferroptosis-related mechanisms in depression and proposes a integrative treatment strategy combining targeted molecular interventions with TCM approaches. The findings offer new perspectives for developing therapeutic interventions, particularly for treatment-resistant depression."

Journal • CNS Disorders • Depression • Inflammation • Mood Disorders • Psychiatry

Therapeutic Reference Ranges for ADHD Drugs in Blood of Children and Adolescents: A Systematic Review by the AGNP TDM-Task Force. (PubMed, Pharmacopsychiatry) - "This study aimed to establish preliminary therapeutic reference ranges for methylphenidate (MPH), d-amphetamine (d-AMP), atomoxetine (ATX), and guanfacine (GFC), based on a systematic review of the existing relevant literature.Therapeutic reference ranges were calculated based on blood concentrations measured in responder children and adolescents with ADHD. For GFC, only one study was eligible, with a mean blood concentration of 7.5 ng/mL in responders.The results provide preliminary recommendations that can serve as reference values for therapeutic drug monitoring in children and adolescents treated with MPH, AMP, ATX, and GFC. Further research is needed to validate or refine the proposed therapeutic ranges."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Clinical Features of Adults With ADHD, Focusing on Their Adherence to Medication (AACAP 2025) - "We examined the adherence and persistence of those who received pharmacotherapy for ADHD, which was with either methylphenidate or atomoxetine. From the results of this study, it could be inferred that misuse and abuse of stimulants may not be common for those who receive a proper diagnosis and an adequate prescription. The bigger concern in clinical practice for adults with ADHD is that they have low compliance for treatment. Clinicians treating adults with ADHD should put more emphasis on adherence to ADHD medication than on abuse or misuse of ADHD medications.ADHD, TREAT, PPC"

Adherence • Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Examining the Effects of Atomoxetine Alone vs Atomoxetine Combined With Risperidone in a Sample of Egyptian Children With ADHD (AACAP 2025) - "Patients with the attention deficit variant responded well to atomoxetine. Patients with the attention-deficit/hyperactivity variant responded well to atomoxetine/antipsychotic (risperidone) combination. Patients with the hyperactivity variant showed good response to antipsychotics (risperidone)."

Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Aggression, Mood Dysregulation, and Treatment Response in Youth With ADHD (AACAP 2025) - "This presentation discusses findings from a crossover study of ADHD youth treated with osmotic-controlled-release oral delivery system (OROS)-methylphenidate (MPH) and atomoxetine (ATX). Stimulants and nonstimulants can each have a role in the treatment of aggression and mood dysregulation in ADHD youth, with interrelationships among ADHD symptoms, aggression, and mood dysregulation contributing to overall response.TREAT, AGG, ADHD"

ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Behavior Disorders • CNS Disorders • Psychiatry

Optimizing ADHD Medication Management: From Stimulants to Nonstimulants in Children and Adolescents (AACAP 2025) - "Specifically, the presentation will cover dosing regimens, side effects, and monitoring considerations for CNS stimulants (eg, methylphenidate, amphetamine salts), alpha-2 adrenergic agonists (eg, guanfacine, clonidine), and NRIs (eg, atomoxetine, viloxazine). CNS stimulants remain the first-line treatment for ADHD, with a 70%-80% response rate in children... Effective ADHD management requires a personalized approach, balancing medication efficacy with tolerability. Clinicians must closely monitor side effects and ensure that treatment aligns with the patient's developmental stage, comorbidities, and individual needs. Continued collaboration with families and frequent follow-up are critical to optimizing long-term outcomes for children and adolescents with ADHD.ADHD, PPC, TREAT"

Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry • Suicidal Ideation

Impact of Pharmacologic ADHD Treatment on Childhood Growth and Eating Patterns (AACAP 2025) - "It will incorporate real-life case examples, visuals, and interactive elements such as real-time polling applications to encourage audience learning and engagement. Long-term methylphenidates (MPH) and likely all psychostimulants are associated with an impact on height and weight in children and adolescents with ADHD, although studies have suggested various effect sizes. Atomoxetine has also been associated with effects on growth in the short term... Effect sizes and the clinical significance of height and weight changes associated with ADHD medications may be small, but growth should be carefully monitored during treatment. Clinicians should advise patients and parents about these risks in the context of possible growth and nutritional outcomes with the risks of ADHD nontreatment. Although they are lacking robust evidence, practical strategies such as timing of doses, caloric supplementation, and medication holidays can be considered on a case-by-case basis.ADHD, MAE, PPC"

Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

ASSESSMENT AND TREATMENT OF AGGRESSION IN YOUTH: INSIGHTS FROM BEHAVIOR PROFILES AND LARGE-SCALE DATA (AACAP 2025) - "The fourth study investigates the impact of aggression and mood dysregulation on ADHD treatment response in a crossover trial of osmotic-controlled release oral delivery system (OROS)-methylphenidate and atomoxetine. RAGA-16 demonstrated strong internal consistency and convergent validity, supporting its utility as a screening tool for severe reactive aggression. These findings advance our understanding of childhood aggression and irritability by refining assessment tools, identifying transdiagnostic subgroups, and uncovering dynamic predictors of symptom trajectories. Improved classification and personalized assessment strategies have the potential to enhance targeted interventions for affected youth.TREAT, IMD, AGG"

ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Pharmacological management of attention deficit hyperactivity disorder in children and adolescents. (PubMed, Aust Prescr) - "Stimulants (methylphenidate, dexamfetamine, lisdexamfetamine) are the main pharmacological treatment for children and adolescents with ADHD and are highly effective at reducing core ADHD symptoms. Non-stimulants such as atomoxetine, clonidine and guanfacine can also be useful in some patients."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Developmental Disorders • Psychiatry

The Role of Pharmacotherapy in Social Cognition, Empathy, and Serum Oxytocin Levels in Children with Attention Deficit Hyperactivity Disorder: A Case-Control Study. (PubMed, Children (Basel)) - "However, the influence of pharmacotherapy, particularly methylphenidate (MPH) and atomoxetine (ATX), on these domains remains underexplored. Pharmacotherapy may enhance social cognition among children with ADHD. Longitudinal studies are warranted to assess the long-term effects of medication on social cognition and empathy."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Global Trends in ADHD Medication Use: Multiple Contexts and Rising Concerns-A Narrative Review. (PubMed, J Clin Med) - "Methylphenidate remained the most widely prescribed drug, although the use of lisdexamfetamine and guanfacine has expanded in recent years...Increasing use of ADHD medications raises important questions about equitable access to treatment, potential overdiagnosis, and the risk of stimulant misuse. These findings highlight the need for continued monitoring of utilization patterns to ensure safe, rational, and equitable ADHD care worldwide."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Pharmacological treatment options for cognitive dysfunction induced by multiple sclerosis: a network meta-analysis. (PubMed, Front Neurol) - "Compared to memantine, fampridine-SR, ginkgo biloba, and melatonin showed inferior effects. Atomoxetine may improve Symbol Digit Modalities Test (SDMT) scores, outperforming donepezil, ginkgo biloba, L-amphetamine, modafinil, and rivastigmine. Additionally, atomoxetine may improve California Verbal Learning Test (CVLT) performance, compared to ginkgo biloba, L-amphetamine, and memantine...However, rivastigmine was found to have a lower likelihood of causing dyspepsia among the treatments assessed. https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024623642."

Journal • Retrospective data • Review • CNS Disorders • Cognitive Disorders • Dyspepsia • Multiple Sclerosis

Real-World Clinical and Economic Impact of Pharmacogenetic-Supported Prescribing in Kids: Results from a Large Canadian Mirror Image Trial (WCPG 2025) - "The study enrolled over 1,900 participants, referred by more than 300 psychiatrists, family physicians, and pediatricians across Alberta, Saskatchewan, British Columbia, and Manitoba. PGx testing revealed that 82% of participants had at least one actionable genotype. The most frequently prescribed PGx-guided psychotropic medications were sertraline (18%), fluvoxamine (9%), risperidone (8%), aripiprazole (7%), and atomoxetine (6%)."

Biomarker • Clinical • HEOR • Real-world • Real-world evidence • Pediatrics • Psychiatry

Pharmacological and dietary treatments for developmental stuttering: a systematic review. (PubMed, Neurosci Biobehav Rev) - "Despite some promising findings, particularly for newer antipsychotics and atomoxetine, methodological limitations prevent definitive treatment recommendations. Key issues included lack of randomised placebo-controlled trials, inconsistent outcome measures, and small sample sizes. Future research requires larger trials with standardized protocols to evaluate treatment efficacy while accounting for individual variability in response and potential adverse effects."

Journal • Review • CNS Disorders

Unveiling Social Media Content Related to ADHD Treatment: Machine Learning Study Using X's Posts over 15 Years. (PubMed, Healthcare (Basel)) - "Methylphenidate, dextroamphetamine, and atomoxetine were the most commonly mentioned medications, especially by patients, who emerged as the most active users among the English tweets. In this study, conducted on X, discussions on ADHD medications highlighted concerns about misuse, adherence, and trivialisation, with clear differences between English and Spanish tweets regarding focus and type of user participation. These findings suggest that monitoring social media can provide early signals about emerging trends, helping clinicians address misconceptions during consultations and informing public health strategies aimed at the safer and more responsible use of ADHD medications."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Cannabidiol Lipid Nanoparticles Stabilize Gut-Brain-Bone Axis Integrity and Enhance Neuroplasticity in Stressed Rats: A Comparison with Atomoxetine and Escitalopram. (PubMed, Int J Mol Sci) - "Histological analysis confirmed that CBD/LNP, ATX, and ESC ameliorated tissue alterations. These findings highlight CBD/LNP as a promising intervention for stress-induced gut-brain-bone axis disruption, supporting its potential as a therapeutic alternative through modulation of microbiota-driven gut-brain communication in stress-associated disorders."

Clinical • Journal • Preclinical • CNS Disorders • Inflammation • Mood Disorders • Psychiatry • BDNF • IL6 • TNFA

Noradrenaline treatment of apathy and impulsivity in participants with Progressive Supranuclear Palsy syndromes (NORAPS) (MDS Congress 2025) - "NORAPS tests the hypothesis that atomoxetine is safe and well tolerated in PSP, with benefits on apathy and impulsivity. A secondary hypothesis to be tested is that behavioural and cognitive outcomes are dependent on baseline integrity of the locus coeruleus noradrenergic system. Given locus coeruleus involvement in various neurodegenerative disorders, findings from NORAPS may have broad transdiagnostic implications."

CNS Disorders • Depression • Mood Disorders • Movement Disorders • Parkinson's Disease • Progressive Supranuclear Palsy • Psychiatry

Treatment of Orthostatic Intolerance (clinicaltrials.gov) - P1/2 | N=150 | Active, not recruiting | Sponsor: Satish R. Raj | Trial completion date: Dec 2027 ➔ Dec 2029 | Trial primary completion date: Dec 2027 ➔ Dec 2029

Trial completion date • Trial primary completion date • Cardiovascular

HISTOLOGICAL INJURY PATTERNS IN CHILDREN WITH DRUG-INDUCED LIVER INJURY (AASLD 2025) - "Causative agents were minocycline (5), azithromycin (3), atomoxetine (3), lamotrigine (2), and nicotine, drospirenone/estradiol, Trikafta, carbamazepine, doxycycline, infliximab, amoxicillin, amoxicillin/clavulanate, and isoniazid (1 each). Children with DILI experienced similar range of pathology as seen in adults, with both hepatocellular and cholestatic liver injury represented. Eosinophilia was seen in less than half, and plasmacytosis in one third of biopsies. While most cases showed mild injury overall, a few showed severe inflammation, necrosis, or bridging fibrosis."

Clinical • Cholestasis • Eosinophilia • Fibrosis • Hepatology • Immunology • Inflammation • Liver Failure • Pediatrics

An atypical presentation of complicated grief in a child with high functioning autism spectrum disorder (ECNP 2025) - "Following psychiatric evaluations, a dual diagnosis of high functioning ASD and attention-deficit/hyperactivity disorder (ADHD) was made, and treatment with atomoxetine 60 mg/day was initiated. In individuals with high functioning autism spectrum disorder complicated grief can present as a more complex and intervention-requiring condition due to social-emotional challenges. In this case, in addition to psychotherapy, risperidone treatment was effective in achieving emotional regulation and facilitating the patient's adaptation to the grieving process [5]. The treatment contributed to both symptom alleviation and improved daily functioning."

Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

CA33 – Risks and benefits of using ADHD medication during pregnancy (ECNP 2025) - "Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital Malformations: A Cohort Study From the International Pregnancy Safety Study Consortium...In utero exposure to methylphenidate, amphetamines and atomoxetine and offspring neurodevelopmental disorders - a population-based cohort study and meta-analysis...Attention-deficit/hyperactivity disorder in pregnancy and the postpartum period. Am J Obstet Gynecol 2024; 231(1):19-35."

ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry